MYOV - Myovant Sciences Ltd.

NYSE - NYSE Delayed Price. Currency in USD
18.29
+0.14 (+0.77%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close18.15
Open18.26
Bid0.00 x 1000
Ask0.00 x 800
Day's Range17.83 - 19.31
52 Week Range12.76 - 27.45
Volume42,444
Avg. Volume61,880
Market Cap1.253B
Beta (3Y Monthly)0.53
PE Ratio (TTM)N/A
EPS (TTM)-3.50
Earnings DateFeb 11, 2019 - Feb 15, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.29
Trade prices are not sourced from all markets
  • Andreas Halvorsen Plunges Into Biotech Company Myovant Sciences
    GuruFocus.com9 days ago

    Andreas Halvorsen Plunges Into Biotech Company Myovant Sciences

    Former tiger cub keeps investing in biotech companies

  • PR Newswire18 days ago

    Roivant Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference

    - In addition to Roivant, four Vants will be presenting at JPM this year NEW YORK and BASEL, Switzerland , Jan. 2, 2019 /PRNewswire/ -- Roivant Sciences today announced that Vivek Ramaswamy , Founder and ...

  • PR Newswirelast month

    Myovant Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference

    BASEL, Switzerland, Dec. 20, 2018 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV), a leading clinical-stage biopharmaceutical company focused on women's health and endocrine diseases, today announced that Lynn Seely, M.D., President and Chief Executive Officer of Myovant Sciences, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Myovant's lead product candidate is relugolix, an oral, once-daily small molecule that acts as a GnRH receptor antagonist.

  • PR Newswire2 months ago

    Myovant Sciences to Participate in Two Upcoming Investor Conferences

    Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of women's health and endocrine diseases. Myovant's lead product candidate is relugolix, an oral, once-daily small molecule that acts as a GnRH receptor antagonist.

  • GlobeNewswire2 months ago

    Recent Analysis Shows Atlas Financial, Royal Dutch Shell, Vaalco Energy, Myovant Sciences, Aerpio Pharmaceuticals, and Wheeler Real Estate Investment Trust Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, Nov. 14, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • PR Newswire2 months ago

    Myovant Provides Corporate Updates and Reports Financial Results for Second Fiscal Quarter Ended September 30, 2018

    - Completed Patient Enrollment in Phase 3 LIBERTY 1 and HERO Trials - - Completed Screening in Phase 3 LIBERTY 2 Trial - - On Track to Announce Top-line Results from All Five Relugolix Phase 3 Clinical ...

  • PR Newswire2 months ago

    Myovant Strengthens Management Team and Adds New Directors to the Board

    - Kim Sablich, Chief Commercial Officer, and Jeff Nornhold, Senior Vice President, Pharmaceutical Operations & Development, join Myovant's Executive Committee - Myrtle Potter, Mark Guinan and Frank Torti, ...

  • PR Newswire3 months ago

    Myovant Sciences Announces Completion of Enrollment in Phase 3 HERO Trial of Relugolix in Men with Advanced Prostate Cancer

    - Top-line data expected in fourth quarter of 2019 BASEL, Switzerland , Oct. 24, 2018 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV) today announced it has completed patient enrollment in its pivotal Phase ...

  • PR Newswire3 months ago

    Myovant Announces Presentation of Data from Phase 1 Trial of MVT-602 at 2018 American Society for Reproductive Medicine (ASRM) Annual Congress

    BASEL, Switzerland, Oct. 10, 2018 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV) today announced the presentation of data from a Phase 1 trial of MVT-602, a novel kisspeptin-1 receptor agonist in development as a potential treatment for female infertility in women as part of assisted reproduction, such as in vitro fertilization (IVF). Results of the study showed that administration of MVT-602 in healthy premenopausal women in the follicular phase produced a dose-related increase in luteinizing hormone concentrations and expected effects on follicle-stimulating hormone and estradiol.

  • Myovant Sciences and Flo Health Partner to Develop Digital Tool to Screen Women for Heavy Menstrual Bleeding
    PR Newswire3 months ago

    Myovant Sciences and Flo Health Partner to Develop Digital Tool to Screen Women for Heavy Menstrual Bleeding

    BASEL, Switzerland and REDWOOD CITY, Calif., Oct. 8, 2018 /PRNewswire/ -- Myovant Sciences (MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, and Flo Health, a company developing the world's fastest growing artificial intelligence (AI)-driven platform for women's health with 22 million active users, announced today a partnership to create a digital tool to screen for heavy menstrual bleeding. Affecting more than 25 percent of women, heavy menstrual bleeding is associated with diseases such as uterine fibroids and can negatively impact a woman's quality of life.

  • PR Newswire5 months ago

    Myovant Sciences to Participate in Two Upcoming Investor Conferences

    Lynn Seely, M.D., Myovant's President and Chief Executive Officer, will present on Wednesday, September 5, 2018, in a session scheduled to begin at 4:20 p.m. ET. The presentation will be featured in a live webcast and can be accessed via the Events page under the Investors and Media section of Myovant's website at www.myovant.com.

  • PR Newswire5 months ago

    Myovant Provides Corporate Update and Reports Financial Results for First Fiscal Quarter Ended June 30, 2018

    - Completed patient screening for Phase 3 LIBERTY 1 Trial - - On track to announce top-line results from all relugolix Phase 3 clinical trials during 2019 - - Ended first fiscal quarter of 2018 with $235.6 ...

  • PR Newswire6 months ago

    Myovant Sciences Ltd. Announces Pricing of $75.0 Million Public Offering of Common Shares

    BASEL, Switzerland, July 12, 2018 /PRNewswire/ -- Myovant Sciences Ltd. (MYOV) ("Myovant"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of women's health and endocrine diseases today announced the pricing of its underwritten public offering of 3,333,334 of its common shares at a price to the public of $22.50 per share. Gross proceeds to Myovant from the offering are expected to be approximately $75.0 million, before deducting underwriting discounts and commissions and estimated offering expenses.  All of the common shares are being offered by Myovant. In connection with this offering, Myovant has granted the underwriters a 30-day option to purchase up to an additional 500,000 of its common shares on the same terms and conditions.  The offering is expected to close on July 17, 2018, subject to customary closing conditions.  Myovant currently intends to use the net proceeds from the offering primarily to fund its clinical development programs, preparations for the potential commercial launch of relugolix, as well as for working capital and other general corporate purposes.

  • PR Newswire6 months ago

    Myovant Sciences Ltd. Announces $75 Million Public Offering of Common Shares

    BASEL, Switzerland, July 11, 2018 /PRNewswire/ -- Myovant Sciences Ltd. (MYOV) ("Myovant"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of women's health and endocrine diseases today announced that it has commenced an underwritten public offering of $75 million of its common shares. All of the common shares are being offered by Myovant. In connection with this offering, Myovant expects to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of its common shares in the offering on the same terms and conditions.

  • PR Newswire6 months ago

    Myovant Sciences Announces Completion of Screening for Phase 3 LIBERTY 1 Study Evaluating Relugolix in Women with Uterine Fibroids

    BASEL, Switzerland, July 10, 2018 /PRNewswire/ -- Myovant Sciences (NYSE:  MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that it has completed screening patients for its LIBERTY 1 study, the first of two Phase 3 replicate studies evaluating relugolix in women with heavy menstrual bleeding associated with uterine fibroids. Uterine fibroids are debilitating and result in heavy menstrual bleeding in millions of women throughout the world, often requiring a hysterectomy.

  • ACCESSWIRE7 months ago

    Blog Exposure - Biohaven Signs Royalty Funding and Stock Purchase Agreements with Royalty Pharma

    LONDON, UK / ACCESSWIRE / June 21, 2018 / If you want access to our free research report on Biohaven Pharma Holding Co. Ltd (BHVN) ("Biohaven"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BHVN as the Company's latest news hit the wire. On June 19, 2018, the Company announced that it has sold tiered, sales-based participation rights on future global net sales of products containing rimegepant (BHV-3000), or BHV-3500, and certain derivative compounds thereof to Royalty Pharma for $100 million. Active-Investors.com is currently working on the research report for Myovant Sciences Ltd (MYOV), which also belongs to the Healthcare sector as the Company Biohaven Pharma Holding.

  • PR Newswire7 months ago

    Myovant Sciences to Present at First Annual Roivant Pipeline Day

    BASEL, Switzerland, June 18, 2018 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health and endocrine diseases, today announced that Lynn Seely, M.D., President and Chief Executive Officer of Myovant Sciences, will present at the first annual Roivant Pipeline Day on July 10, 2018 at 2:30 p.m. ET. A live webcast will be available via the Events page under the Investors and Media section of Myovant's website at www.myovant.com. Roivant Pipeline Day will be held on Tuesday, July 10, 2018 in New York City.

  • Myovant Sciences Ltd (NYSE:MYOV): Earnings Expected To Remain Subdued
    Simply Wall St.7 months ago

    Myovant Sciences Ltd (NYSE:MYOV): Earnings Expected To Remain Subdued

    In March 2018, Myovant Sciences Ltd (NYSE:MYOV) announced its most recent earnings update, which revealed company earnings became less negative compared to the previous year’s level – great news forRead More...

  • PR Newswire7 months ago

    Myovant Provides Corporate Update and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2018

    - On track for top-line results from all relugolix Phase 3 clinical studies during 2019 - Ended Fiscal Year 2017 with $200.6 million in cash and committed financings - Raised approximately $80.1 million ...

  • PR Newswire9 months ago

    Myovant Sciences and PERIOD. Inc. Launch Partnership Focused on Empowering Women to Elevate the Conversation Around Period Health

    Inc., a youth-led non-profit organization focused on menstrual equity, today announced a partnership to elevate the conversation around period health, including the Ask Me About Periods campaign on college campuses across the country. In recognition of this partnership, the two organizations are hosting Public Health and PERIOD, a panel with Lynn Seely, M.D., President and CEO of Myovant Sciences, Kathleen Sebelius, a member of Myovant's Board of Directors and former Secretary of the U.S. Department of Health and Human Services (HHS), and Ana Langer, M.D., Professor of the Practice of Public Health at the Harvard T.H. Chan School of Public Health.

  • PR Newswire11 months ago

    Myovant Sciences to Present at Upcoming Investor Conferences

    BASEL, Switzerland , March 6, 2018 /PRNewswire/ -- Myovant Sciences (NYSE: MYOV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women's health ...

  • PR Newswire11 months ago

    Myovant Sciences Provides Corporate Update and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2017

    - Positive results reported by Takeda in two Phase 3 clinical studies of relugolix for the treatment of uterine fibroids - Secured up to $140 million in flexible financing commitments BASEL, Switzerland ...